Almitrine: a possible therapeutic strategy for COVID-19?
DOI:
https://doi.org/10.34024/rnc.2020.v28.10941Keywords:
dysautonomia, neurology, Coronavirus InfectionsAbstract
Coronavirus disease 2019 (COVID‐19) remains with no specific treatment, despite the efforts of many scientists around the world. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) penetrates human host banknotes through interaction with angiotensin-converting enzyme 2 and transmembrane protease, serine 2 (TMPRSS2) receptors, located at respiratory tract (upper and lower) and the olfactory epithelium (pathway to the Central Nervous System). The virus causes COVID-19 and sometimes a Severe Acute Respiratory Syndrome (SARS). Several neurological manifestations can be associated with the infection. The SARS-COV-2 neurotropism for cardiorespiratory centers, causing autonomic damage, may contribute to respiratory failure. Almitrine is a respiratory stimulant drug, used in chronic hypoxemic diseases. Almitrine acts in peripheral chemoreceptors and could be a potential treatment for the optimization of chemoreceptors, improving the respiratory control affected by the SARS‐CoV‐2 in patients with COVID-19.
Metrics
References
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;Epub ahead of print. https://doi.org/10.1002/jmv.25728
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020;277:2251-61.
https://doi.org/10.1007/s00405-020-05965-1
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;1-13. Epub ahead of print. https://doi.org/10.1007/s00415-020-09974-2
Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020;20:697-706. https://doi.org/10.1016/S1473-3099(20)30200-0
Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 2020;22:80-5. https://doi.org/10.1016/j.micinf.2020.02.002
Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. Mol Pharmacol 2020;97:351-3. https://doi.org/10.1124/molpharm.120.000014
Dube M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43. J Virol 2018;92:e00404-18.
https://doi.org/10.1128/JVI.00404-18
Li YC, Bai WZ, Hirano N, Hayashida T, Hashikawa T. Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells. Virus Res 2012;163:628-35.
https://doi.org/10.1016/j.virusres.2011.12.021
Li YC, Bai WZ, Hirano N, Hayashida T, Taniguchi T, Sugita Y, et al. Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication. J Comp Neurol 2013;521:203-12. https://doi.org/10.1002/cne.23171
Md Insiat Islam Rabby. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci 2020;23:58-64. https://doi.org/10.18433/jpps31002
Smith PD, Gotz VP, Ryerson GG. Almitrine bismesylate. Drug Intell Clin Pharm 1987;21:417-21.
https://doi.org/10.1177/106002808702100503
Moreira TS, Takakura AC, Colombari E, Guyenet PG. Central chemoreceptors and sympathetic vasomotor outflow. J Physiol 2006;577:369-86. https://doi.org/10.1113/jphysiol.2006.115600
Downloads
Published
Issue
Section
How to Cite
Accepted 2020-10-23
Published 2020-10-23
